TY - JOUR T1 - Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1338 LP - 1340 DO - 10.1136/annrheumdis-2022-222189 VL - 81 IS - 9 AU - Josefina Durán AU - Paula Isabel Burgos AU - Nicole Le Corre AU - Cinthya Ruiz Tagle AU - Constanza Martinez-Valdebenito AU - Mauricio Castro AU - Valentina Metcalfe AU - Paula Niemann AU - M Elvira Balcells Y1 - 2022/09/01 UR - http://ard.bmj.com/content/81/9/1338.abstract N2 - CoronaVac, an inactivated SARS-CoV-2 vaccine, has been administered in over 100 countries worldwide, but its immunity wanes quickly over time.1 In consequence, boosters are being recommended.We evaluated the immunogenicity of an mRNA vaccine booster (BNT162b2) in inflammatory arthritis (IA) patients with biologic treatments previously vaccinated with CoronaVac. Consenting adults with IA followed at Red Salud UC-CHRISTUS (Chile), who were on anti-TNF, anti-IL6 or anti-IL17 biologics, vaccinated with CoronaVac (0, 28), were eligible. Those with a SARS-CoV-2 infection history were excluded. Humoral response was assessed by measuring IgG SARS-CoV-2 total antibody (Tab) and neutralising antibody (Nab) within 7 days and 4 weeks after the booster. DMARDs were not discontinued.The primary outcome was the proportion of participants with positive SARS-CoV-2 Nab 4 weeks after the BTN162b2 booster. A neutralisation of 30% or more at a 1:10 dilution was considered positive.2 Dichotomous and continuous variables were compared using the McNemar or Wilcoxon signed-rank test. Confounding and effect modifiers of covariates were explored using binary regression models.Seventy-six individuals were included. Mean age was 51.9 (SD 11.3) and 73.6% were female. Mean years since diagnosis were … ER -